Healthcare entity
CRISPR Therapeutics is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Each story carries 11 original sources on average, compared with 3.3 for the broader beat in this window. The 57-day window averages about 0.2 stories each week.
Last mentioned: Sep 3, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
CRISPR Therapeutics is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Each story carries 11 original sources on average, compared with 3.3 for the broader beat in this window. The 57-day window averages about 0.2 stories each week. Their average consequence score of 6.5 runs above the beat's 5.9 for that window. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category. This profile follows 2 Healthcare stories mentioning Casgevy across the period from July 9, 2026 to September 3, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 457 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Casgevy. Shared-story counts are live from our verified record — not editorial picks.
Label expansion
FDA expands Casgevy’s indication to include patients as young as two years old, enabling earlier intervention.
Casgevy approval
FDA approves Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 12 and older.
FDA expansion of Casgevy to children as young as two could enable earlier SCD/TDT intervention before irreversible organ damage. Health systems must now address cell therapy logistics, payer coverage, and the $2.2M cost.
The FDA’s approval of Casgevy for children as young as two promises to shift pediatric sickle cell care from lifelong management to a one-time curative intervention, but raises urgent questions about cost, access, and health equity.
Casgevy is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
